Common uses of Arcoxia (etoricoxib)
Arcoxia is a prescription nonsteroidal anti-inflammatory drug (NSAID) designed to reduce pain and inflammation. Clinicians commonly recommend etoricoxib for osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis—conditions characterized by chronic joint pain and stiffness. It is also used for short-term management of acute pain states such as acute gouty arthritis, postoperative dental pain, and primary dysmenorrhea. In these settings, Arcoxia can offer targeted relief with once-daily dosing, which many patients find convenient.
Unlike traditional NSAIDs that inhibit both COX-1 and COX-2 enzymes, etoricoxib selectively inhibits COX-2. This selectivity is intended to maintain anti-inflammatory efficacy while reducing, but not eliminating, the risk of gastrointestinal (GI) irritation and ulcers associated with nonselective NSAIDs. Importantly, COX-2 selectivity does not remove cardiovascular risks inherent to the NSAID class; prescribers weigh these considerations when deciding if Arcoxia is appropriate.
How Arcoxia works (mechanism of action)
Inflammation triggers production of prostaglandins via cyclooxygenase (COX) enzymes. COX-2 is upregulated at inflamed sites and mediates pain, swelling, and fever. By selectively inhibiting COX-2, Arcoxia lowers prostaglandin synthesis in inflamed tissues, reducing pain and improving function. COX-1, which helps protect the stomach lining and supports platelet function, is relatively spared—one reason etoricoxib may have a lower rate of GI ulceration than some nonselective NSAIDs. However, all NSAIDs can still cause GI events, especially with prolonged use, high doses, or concurrent aspirin.
Dosage and direction for Arcoxia
Dosing varies by indication and individual factors. The following are commonly used adult regimens in countries where etoricoxib is approved; always follow your clinician’s instructions and local labeling:
• Osteoarthritis: 30–60 mg once daily (lowest effective dose preferred).
• Rheumatoid arthritis: 60–90 mg once daily, based on response and risk profile.
• Ankylosing spondylitis: 60–90 mg once daily.
• Acute gout: 120 mg once daily for the shortest duration, typically up to 8 days.
• Acute pain (e.g., dental pain, dysmenorrhea): 60–120 mg once daily for the shortest duration possible.
The maximum recommended daily dose is 120 mg, and higher doses or extended use at 120 mg increase risk without improving safety. Take Arcoxia at the same time each day, with or without food; taking it with food may slow onset slightly but can improve gastric comfort. For older adults or those with comorbid conditions, prescribers often start at the lowest effective dose and reassess regularly.
Hepatic and renal considerations: In moderate hepatic impairment, lower dosing (e.g., maximum 60 mg daily) may be advised; etoricoxib is not recommended in severe hepatic impairment. In severe renal impairment (e.g., creatinine clearance less than 30 mL/min), etoricoxib is generally contraindicated. Your clinician will determine the safest regimen based on labs and overall risk.
Precautions before using Arcoxia
• Cardiovascular risk: Selective COX-2 inhibitors, including etoricoxib, have been associated with an increased risk of thrombotic events (e.g., myocardial infarction, stroke), particularly at higher doses and longer durations. Arcoxia is typically avoided in patients with established ischemic heart disease, peripheral arterial disease, cerebrovascular disease, or heart failure, and used cautiously in those with cardiovascular risk factors such as hypertension, hyperlipidemia, diabetes, or smoking history.
• Blood pressure and fluid retention: NSAIDs may elevate blood pressure and promote sodium/water retention. Monitor blood pressure regularly, especially after initiation or dose changes. Patients with edema, heart failure, or kidney disease require close supervision.
• Gastrointestinal safety: Though GI ulcer risk may be lower than with nonselective NSAIDs, Arcoxia can still cause dyspepsia, gastritis, ulcers, and bleeding. Risk rises with age, prior ulcer/bleed, high doses, prolonged use, concurrent alcohol, corticosteroids, SSRIs/SNRIs, anticoagulants, antiplatelets (including low-dose aspirin), and H. pylori infection. Gastroprotection (e.g., a PPI) may be considered in high-risk individuals.
• Renal and hepatic function: NSAIDs can precipitate renal impairment, especially in volume-depleted states or with ACE inhibitors/ARBs and diuretics. Assess baseline renal function and monitor periodically. In hepatic disease, use only if benefits outweigh risks, with careful monitoring of liver enzymes and clinical status.
• Hypersensitivity: Avoid Arcoxia in patients with hypersensitivity to etoricoxib or other NSAIDs, including those with aspirin-sensitive asthma or a history of NSAID-induced urticaria, angioedema, or bronchospasm.
• Pregnancy and breastfeeding: Prostaglandin synthesis inhibitors can harm fetal circulation (e.g., premature closure of the ductus arteriosus), especially in the third trimester. Generally avoid etoricoxib during pregnancy and while trying to conceive. Its use during breastfeeding is not recommended due to limited data. Discuss safer alternatives with your clinician.
• Fertility: NSAIDs may temporarily affect ovulation. Consider this if you are attempting to become pregnant.
Contraindications to Arcoxia
Arcoxia is generally contraindicated in the following scenarios: active peptic ulcer or gastrointestinal bleeding; severe hepatic impairment; severe renal impairment (e.g., CrCl <30 mL/min); established ischemic heart disease, cerebrovascular disease, or peripheral arterial disease; heart failure (particularly moderate to severe); uncontrolled hypertension; known hypersensitivity to etoricoxib or other NSAIDs (including aspirin-exacerbated respiratory disease). Do not use concomitantly with other NSAIDs, including selective COX-2 inhibitors.
Possible side effects of Arcoxia
Common reactions can include headache, dizziness, dyspepsia, heartburn, abdominal discomfort, nausea, diarrhea, peripheral edema, elevated blood pressure, fluid retention, and fatigue. These are often dose-related and may improve by using the lowest effective dose for the shortest duration.
Serious adverse effects—seek urgent medical help if you experience chest pain, sudden shortness of breath, weakness on one side of the body, slurred speech, black or bloody stools, vomiting blood, severe abdominal pain, significant swelling or rapid weight gain, decreased urination, yellowing of the skin or eyes, severe skin reactions (e.g., rash with blistering or peeling), or facial swelling and wheezing suggestive of anaphylaxis.
Laboratory changes can include elevations in transaminases and, less commonly, changes in kidney function or hemoglobin if occult GI blood loss occurs. Regular follow-up is prudent for patients on ongoing therapy.
Drug interactions with etoricoxib (Arcoxia)
• Anticoagulants (e.g., warfarin): Etoricoxib can increase INR; close monitoring is necessary when starting or adjusting doses.
• Antiplatelets and aspirin: Combining increases GI bleeding risk; COX-2 selectivity does not confer protection when aspirin is added.
• ACE inhibitors/ARBs/diuretics: Concomitant use can reduce renal perfusion and function, especially in older or volume-depleted patients; monitor renal function and blood pressure.
• Lithium: NSAIDs can elevate lithium concentrations; monitor levels and adjust as needed.
• Methotrexate: Etoricoxib may increase methotrexate levels; monitor for toxicity when co-administered.
• Cyclosporine or tacrolimus: Potential for increased nephrotoxicity; consider close renal monitoring.
• Hormonal contraceptives/estrogens: Etoricoxib can increase exposure to ethinyl estradiol; this may modestly heighten thrombotic risk—evaluate the overall risk profile.
• CYP modulators: Strong inducers like rifampin may reduce etoricoxib levels; potent inhibitors (e.g., ketoconazole) can increase levels modestly—clinical significance varies.
• Other NSAIDs and SSRIs/SNRIs: Additive GI bleeding risk; avoid duplicate NSAID therapy and use caution with serotonergic antidepressants.
Always provide your healthcare professional with a complete list of medications, supplements, and herbal products before starting Arcoxia.
Missed dose guidance for Arcoxia
If you miss a dose, take it when you remember unless it is almost time for your next dose. Do not double up to make up for a missed tablet. Resume your regular schedule the next day. Consistent once-daily dosing at the same time can improve adherence.
Overdose information
Etoricoxib overdose may cause symptoms such as nausea, vomiting, abdominal pain, drowsiness, dizziness, hypertension, and renal dysfunction. There is no specific antidote. Management is supportive: consider activated charcoal if presentation is within approximately one hour of ingestion and airway is protected; monitor vital signs, renal function, and for GI bleeding. Due to high protein binding, dialysis is unlikely to significantly enhance elimination. Seek urgent medical care if overdose is suspected.
Storage and handling of Arcoxia
Store tablets at controlled room temperature (typically 20–25°C/68–77°F), with permitted excursions per local labeling. Keep in the original blister or container to protect from moisture and light. Do not use past the expiration date. Keep out of reach of children and pets. Do not share prescription medicines with others, even if symptoms appear similar.
Arcoxia in special populations
• Older adults: Greater susceptibility to cardiovascular, renal, and GI adverse effects warrants cautious dosing and periodic monitoring.
• Adolescents: Indications and dosing vary by country; in many regions etoricoxib is not approved for pediatric use—follow local guidance.
• Patients with multiple comorbidities: Consider drug–drug interactions, baseline renal/hepatic status, and overall cardiovascular risk before initiating therapy.
U.S. sale and prescription policy: what to know about buying Arcoxia online
Arcoxia (etoricoxib) is not FDA-approved for sale in the United States. In general, U.S. law requires a valid prescription from a licensed clinician for prescription medicines, and the FDA restricts importing non–FDA-approved drugs for personal use. Claims of “no prescription needed” or “OTC Arcoxia” targeting U.S. consumers can signal unlicensed or unsafe sources. For your safety, avoid sites that bypass medical review, obscure their location or licensure, or do not require appropriate patient information.
HealthSouth Rehabilitation Hospital of Manati supports legal, structured access and patient safety. Rather than bypassing clinical oversight, the pharmacy’s model emphasizes appropriate evaluation: where permitted by local regulations, patients may be connected to licensed clinicians for telehealth assessment, electronic authorization, and pharmacy dispensing. In some jurisdictions outside the U.S., that can mean obtaining Arcoxia without a traditional paper prescription while still meeting the legal requirement for clinician approval and safe dispensing. Availability depends on your location, governing laws, and clinical eligibility.
If you reside in the U.S., discuss alternatives that are FDA-approved and clinically appropriate for your condition. If you are outside the U.S., verify that any online pharmacy is licensed in its jurisdiction, requires proper health information, provides pharmacist counseling, protects your data, and ships in tamper-evident packaging. Look for accreditation or regulatory listings and transparent contact information. When in doubt, consult your healthcare professional before purchasing any medicine online.
Important: This article provides general information and is not a substitute for professional medical advice. Always use the lowest effective dose for the shortest duration consistent with your treatment goals, and seek personalized guidance from a qualified clinician about whether etoricoxib is right for you.
